Psychosis of Parkinson's disease: Serotonin 2A receptor inverse agonists as potential therapeutics

David M. Weiner*, Kimberly E. Vanover, Mark R. Brann, Herbert Y. Meltzer, Robert E. Davis

*Corresponding author for this work

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.

Original languageEnglish (US)
Pages (from-to)815-819
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number7
StatePublished - Jul 1 2003

Fingerprint

Receptor, Serotonin, 5-HT2A
Psychotic Disorders
Parkinson Disease
Therapeutics
Movement Disorders
Synaptic Transmission
Antipsychotic Agents

Keywords

  • Clozapine
  • Inverse agonist
  • Parkinson's disease
  • Psychosis
  • R-SAT
  • Serotonin 2A receptor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Weiner, David M. ; Vanover, Kimberly E. ; Brann, Mark R. ; Meltzer, Herbert Y. ; Davis, Robert E. / Psychosis of Parkinson's disease : Serotonin 2A receptor inverse agonists as potential therapeutics. In: Current Opinion in Investigational Drugs. 2003 ; Vol. 4, No. 7. pp. 815-819.
@article{4f76d9ed8db9497081922aebf74ed529,
title = "Psychosis of Parkinson's disease: Serotonin 2A receptor inverse agonists as potential therapeutics",
abstract = "Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.",
keywords = "Clozapine, Inverse agonist, Parkinson's disease, Psychosis, R-SAT, Serotonin 2A receptor",
author = "Weiner, {David M.} and Vanover, {Kimberly E.} and Brann, {Mark R.} and Meltzer, {Herbert Y.} and Davis, {Robert E.}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "4",
pages = "815--819",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
number = "7",

}

Psychosis of Parkinson's disease : Serotonin 2A receptor inverse agonists as potential therapeutics. / Weiner, David M.; Vanover, Kimberly E.; Brann, Mark R.; Meltzer, Herbert Y.; Davis, Robert E.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 7, 01.07.2003, p. 815-819.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Psychosis of Parkinson's disease

T2 - Serotonin 2A receptor inverse agonists as potential therapeutics

AU - Weiner, David M.

AU - Vanover, Kimberly E.

AU - Brann, Mark R.

AU - Meltzer, Herbert Y.

AU - Davis, Robert E.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.

AB - Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.

KW - Clozapine

KW - Inverse agonist

KW - Parkinson's disease

KW - Psychosis

KW - R-SAT

KW - Serotonin 2A receptor

UR - http://www.scopus.com/inward/record.url?scp=0142094608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142094608&partnerID=8YFLogxK

M3 - Review article

C2 - 14619402

AN - SCOPUS:0142094608

VL - 4

SP - 815

EP - 819

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 7

ER -